Combination of intralesional verapamil and oral antioxidants for P eyronie's disease: a prospective, randomised controlled study

Summary The aim of this study was to evaluate the efficacy of the association of intralesional verapamil ( ILV ) injection with oral antioxidants compared with ILV monotherapy in patients with early onset of P eyronie's disease ( PD ) at 12‐week follow‐up. Group A ( n  = 52) received ILV 10 mg weekly for 12 weeks, while group B ( n  = 53) received ILV 10 mg weekly for 12 weeks + antioxidants orally one tablet once a day for 3 months. The main efficacy outcomes were the change in plaque size ( PS ), penile curvature ( PC ), visual analogue score ( VAS ), IIEF ‐15 and IIEF ‐15 subdomains. Both groups showed significant improvement from baseline to week 12 relative to PS and PC , while group B also in IIEF ‐15 score (mean difference: 5.51, P  < 0.01) and VAS (mean difference: −2.71, P  < 0.01). No significant differences were observed between both groups in PS and PC . Finally, both groups showed significant increase in orgasmic function ( IIEF ‐ OF ) and overall satisfaction ( IIEF ‐ OS ), while group B showed significant improvement also in intercourse satisfaction ( IIEF ‐ IS ). Significant differences were found relative to IIEF ‐ OF , IIEF ‐ IS , IIEF ‐ OS and VAS scores in the group B compared with group A. Patients affected by PD may benefit from combination treatment with ILV and oral antioxidants thanks to the improvement in IIEF ‐ OF , IIEF ‐ IS and IIEF ‐ OS at 12 weeks.